Corony Vire Us Fakery
by Brian Shilhavy
Editor, Health Impact News
Link is below article for more information
The corporate media news cycle this week is once again promoting fear in the American population by claiming that COVID cases are again on the rise in “hot spots,” prompting calls for more lockdowns and other measures, including many states now requiring people to wear face masks in public.
Two key pieces of information are missing from almost all of these reports in the corporate media: death rates (even by their own statistics) are NOT increasing but holding steady or even decreasing, and inaccuracy with the tests themselves are still widespread.
A report earlier this month out of Wichita Falls, Texas, for example, revealed that testing of residents and staff at a medical facility revealed many positive results, but since none of them were sick, they retested 20 of them, and the second test result was negative in all 20 of them.
In a Facebook post-Monday night Sheridan Medical Lodge reported that 78 residents and staff members tested positive for COVID-19 during routine testing conducted on May 25 however after retesting 20 staff and residents the test came back negative.
According to the post, 46 residents and 32 staff members tested positive during routine facility testing.
All positive cases were asymptomatic. According to the post, it is unusual for cases at a nursing facility to not show any symptoms which prompted a retest of 20 residents and staff.
The results of all 20 retests have come back negative for COVID-19. (Source.)
The national corporate media franchises would probably never publish something like this because it doesn’t fit their narrative for the Pandemic.
They do report inaccuracies with testing, however, if it does fit their narrative, meaning that tests are inaccurate in the sense that there should be more positive results, especially if it is a test promoted by President Trump, such as Abbott’s fast COVID-19 test.
FierceBiotech, a pharmaceutical marketing publication, reported:
In mid-May, the Food and Drug Administration issued a rare public warning about an Abbott Laboratories COVID-19 test that for weeks had received high praise from the White House because of its speed: Test results could be wrong.
The agency at that point had received 15 “adverse event reports” about Abbott’s ID NOW rapid COVID-19 test suggesting that infected patients were wrongly told they did not have the coronavirus, which had led to the deaths of tens of thousands of Americans. The warning followed multiple academic studies showing higher “false negative” rates from the Abbott device, including one from New York University (NYU) researchers who found it missed close to half of the positive samples detected by a rival company’s test.
But then, in a move that confounded lab officials and other public health experts, a senior FDA official later that month said coronavirus tests provided outside lab settings would be considered useful in fighting the pandemic even if they miss 1 in 5 positive cases—a worrisome failure rate.
The FDA has now received a total of 106 reports of adverse events for the Abbott test, a staggering increase. The agency has not received a single adverse event report for any other point-of-care tests meant to diagnose COVID-19, an agency spokesperson said.
In a statement, Abbott Laboratories said the NYU research was “flawed” and “an outlier,” citing studies with higher accuracy rates.
Though the Abbott rapid test is one of over 100 COVID-19 diagnostic tests to receive FDA emergency use authorization during the pandemic, President Donald Trump has featured the product in the White House Rose Garden, and the Department of Health and Human Services’ (HHS’) preparedness and response division has issued more than $205 million worth of contracts to buy the test, according to federal contract records. (Source.)
About the only truth the public can ascertain from all of these conflicting reports is, the COVID tests simply are not accurate.
As the FierceBiotech publication noted, over 100 COVID-19 diagnostic tests have received FDA emergency use authorization to fast-track them and bring them to market.